NASDAQ OMX

XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer

Dela

AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator, Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai. A total of 16 patients are expected to be enrolled in the study.

Dr. Hendifar commented, "We are excited to enroll our first patient in this novel combinatorial therapy for the treatment of advanced pancreatic cancer and cachexia. This is the first attempt to add an anti-inflammatory therapy to standard chemotherapy in an effort to improve the performance, quality of life, and survival in patients with this disease."

The study will also assess overall and progression free survival as well as evaluate the relationship between treatment tolerance and patient functional status. Various secondary measures, including changes in lean body mass, weight stability and levels of systemic inflammation will also be monitored. Onivyde will be given intravenously with MABp1 and 5-fluorouraci l /folinic acid every two weeks until disease progression.

The prognosis for advanced pancreatic cancer remains poor despite decades of studies [1].  The 5-year survival has remained close to 5%, unchanged despite improvements in chemotherapeutics, surgical outcomes, and diagnostic techniques [1, 2].  Other than multi-agent cytotoxic therapy there have been no treatment advances for pancreatic cancer or its associated cachexia.

MABp1 was found to improve clusters of symptoms that included reduced pain, fatigue, improved appetite and increased lean body mass in advanced cancer patients. Patients that had these improvements were found to have less tumor progression, substantial reduced serious adverse events related to disease, and about a three-fold improvement in survival [3].

About True Human(TM) Therapeutic Antibodies
XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930

  1. Li, D., et al.,  Pancreatic cancer.  Lancet, 2004.  363 (9414): p. 1049-57.
  2. Panagiotarakou, M., et al.,  Use of supportive care for symptom management in pancreatic cancer: application of clinical research to patient care.  Jop, 2012.  13 (4): p. 342-4.
  3. Hickish T., et al.,  MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol. 2017 Feb;18(2):192-201.



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Hoylu AB: Hoylu VD ökar ägande23.5.2018 08:30Pressmeddelande

Malmö, Sverige, 23 maj 2018 - Hoylu VD, Stein Revelsby har köpt 200 000 aktier (cirka 1,3%) i Hoylu till ett genomsnittspris på 4,31 per aktie. Hans totala innehav per 23 maj är 518 975 aktier och 625 900 optioner. För mer information, kontakta: Stein Revelsby, VD Hoylu +1 213 440 2499 Email: sr@hoylu.com Karl Wiersholm, CFO Hoylu +1 425 829 2316 Email: kw@hoylu.com Om Hoylu Hoylu är ett innovativt företag som levererar lösningar för digitala arbetsytor. Hoylu Suite är det oumbärliga verktyget som möjliggör för företag att leverera högkvalitativt samarbete på den moderna arbetsplatsen med funktionen att använda vilken enhet som helst, för att arbeta smartare och roligare inom olika branscher som såsom teknik, läkemedel, konstruktion, entreprenad, tillverkning, resor, gästfrihet, grafisk design och många fler. Kortnamn: Hoylu Marknadsplats: Nasdaq First North Stockholm Certified Adviser: Mangold Fondkommission AB +46 (0) 8 50 301 550 Publicering Denna information lämnades, genom ovanstå

Hoylu AB: Hoylu CEO increases ownership23.5.2018 08:30Pressmeddelande

Malmo, Sweden, May 23, 2018 - Hoylu CEO, Stein Revelsby has purchased 200,000 shares (approximately 1.3%) in Hoylu at an average price of SEK 4.31 per share. His total holding per May 23 is 518,975 shares and 625,900 options. For more information, please contact: Stein Revelsby, CEO Hoylu + 1 213 440 2499 Email: sr@hoylu.com Karl Wiersholm, CFO Hoylu + 1 425 829 2316 Email: kw@hoylu.com About Hoylu Hoylu delivers innovative solutions to allow global collaborative teams plan, create and share information that will enrichen the user experience in the virtual office. The Hoylu Suite delivers a comprehensive set of personalized digital workspaces to enable teams across locations, on any device, to work smarter and with more fun across major industries including Engineering, Education, Pharmaceutical, Construction, Manufacturing, Graphic Design and many more. For more information visit: Www.hoylu.com or Www.introduce.se/foretag/hoylu Ticker: Hoylu Marketplace: Nasdaq First North Stockholm C

DealCloud announces global expansion, opening of EMEA Headquarters23.5.2018 08:00Pressmeddelande

LONDON, May 23, 2018 (GLOBE NEWSWIRE) -- DealCloud, a technology leader for deal & relationship management in the private capital markets, announces the opening of its EMEA headquarters in Holborn, London, United Kingdom. With the opening of the regional headquarters in London, DealCloud operates out of 4 offices globally. Supporting a rapidly growing client base in the region, DealCloud now provides implementation services, client support, and account management through a dedicated team based out of the London office. "We work closely with every client to tailor our exceptional technology and capabilities to their specific process," says DealCloud Co-Founder and Chief Revenue Officer Ben Harrison. "We are committed to delivering the best possible results for our clients, and we believe growing our team in London is the best way to do this." "Supporting dozens of clients in EMEA today, and adding new clients every week, we are excited about the impact our office expansion will have wit

BIMobject AB: BIMobject acquires Dubai Media City-based social media platform The BIM Hub23.5.2018 08:00Pressmeddelande

BIMobject AB, listed at Nasdaq First North, has today acquired all companies that are part of The BIM Hub Group. The group is based in Dubai, United Arab Emirates, and in England. BIMobject takes over some employees, customer agreements, technical platforms, domains, trademarks and all customer data as well as relationships on thebimhub.com . The BIM Hub is a privately-owned web platform with operations in Dubai, United Arab Emirates, and West Yorkshire, England. The BIM Hub is a professional social media platform for BIM users, property owners, architects, engineers and contractors as well as project managers, property managers and facility managers. The platform's focus is to offer content such as educational materials, presentations, standards, white papers, videos, news, and events. In addition, there are various forums adapted for the construction industry, working with or in connection with the emerging BIM industry. The BIM Hub is advertising-funded, but BIMobject's intention is

BIMobject AB: BIMobject förvärvar sociala medier-plattformen The BIM Hub med huvudkontor i Dubai Media City23.5.2018 08:00Pressmeddelande

BIMobject AB (publ), noterat vid Nasdaq First North, har idag förvärvat samtliga bolag som ingår i The BIM Hub group med bas i Dubai, Förenade Arabemiraten och i England. Bolaget övertar viss personal, kundavtal, teknisk plattform, domäner, varumärken och all kunddata samt relationer på sociala medier-plattformen thebimhub.com . The BIM Hub är en privatägd webbplattform med verksamhet i Dubai, Förenade Arabemiraten, och West Yorkshire i England. The BIM Hub är en professionell sociala medier-plattform som samlar BIM-användare, fastighetsägare, arkitekter, ingenjörer och byggentreprenörer samt projektledare och fastighets- och anläggningsförvaltare. Plattformens fokus är att erbjuda innehåll som exempelvis utbildningsmaterial, presentationer, standards, white papers, videos samt nyheter och event. Därtill finns olika forum anpassat för byggindustrin som arbetar med eller i anslutning till den framväxande BIM-industrin. The BIM Hub är reklamfinansierad men BIMobjects avsikt är att snaras

Northland Power Announces Retirement of CEO John Brace and Appointment of Mike Crawley as Chief Executive Officer, Effective August 4, 201823.5.2018 01:27Pressmeddelande

TORONTO, May 22, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. ("Northland") (TSX:NPI) today announced that Chief Executive Officer John Brace will retire on August 4, 2018 after 30 years with the company. Mike Crawley, currently Northland's Executive Vice President, Development has been appointed to the role of Chief Executive Officer, effective August 4, 2018. Mr. Brace and Mr. Crawley will work together to ensure a smooth transition. Mr. Brace will continue to serve as a Director of Northland. John joined Northland in 1988, shortly after the company was founded. He was appointed Chief Executive Officer in 2005. He has steered Northland through many of its projects, initiatives and growth. Under his leadership, the company has grown to its current enterprise value of $12 billion. John was appointed to Northland's Board of Directors on April 4, 2018, and along with Northland's other board members, will stand for re-election at Northland's Annual General Meeting on May 23rd, 2018. Mike

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum